1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,970 | 6,190 | 12.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.02. | Biocytogen verkündet klinischen Meilenstein: Erster Patient in Phase-1-Studie von IDEAYAs erstklassigem B7H3/PTK7-bispezifischen TOP1-ADC IDE034 behandelt | 526 | Business Wire | IDE034 ist ein B7H3/PTK7-bispezifisches TOP1 ADC, das darauf ausgelegt ist, Tumorzellen, die sowohl B7H3 als auch PTK7 exprimieren, bevorzugt anzugreifen. Es wird derzeit sowohl als Monotherapie... ► Artikel lesen | |
| 26.02. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR 2025 | 1 | HKEx | ||
| 12.02. | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.02. | BIOCYTOGEN-B (02315): (1) POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 12, 2026; (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR; ... | - | HKEx | ||
| 29.01. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT OF ESTIMATED ANNUAL RESULTS FOR THE YEAR 2025 | 3 | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR; AND NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 26.01. | BIOCYTOGEN-B (02315): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 4 | HKEx | ||
| 12.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT EXPANDED COLLABORATION WITH ACEPODIA THROUGH OPTION-BASED EVALUATION FRAMEWORK FOR FIRST-IN-CLASS DUAL-PAYLOAD ... | 1 | HKEx | ||
| 09.01. | Biocytogen und Acepodia erweitern Kooperation durch optionsbasiertes Evaluierungsmodell für bispezifische und Dual-Payload-First-in-Class-ADC (BsAD2C) | 477 | Business Wire | Die erweiterte Zusammenarbeit knüpft an die jüngsten gemeinsamen Entwicklungsanstrengungen von Acepodia und Biocytogen zur Evaluierung ausgewählter bispezifischer Antikörper- und Dual-Payload-ADC-Programme... ► Artikel lesen | |
| 09.01. | Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C) | 321 | Business Wire | Expanded collaboration builds on Acepodia and Biocytogen's recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs
Biocytogen Pharmaceuticals (Beijing)... ► Artikel lesen | |
| 31.12.25 | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 31.12.25 | BIOCYTOGEN-B (02315): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 24.12.25 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT | 2 | HKEx | ||
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Börsengang am STAR-Markt ab und wird zum ersten globalen Arzneimittelentwickler mit "H+A"-Status | 548 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine... ► Artikel lesen | |
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 586 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing... ► Artikel lesen | |
| 10.12.25 | BIOCYTOGEN-B (02315): NEXT DAY DISCLOSURE RETURNS | 4 | HKEx | ||
| 10.12.25 | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 614 | Business Wire | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,034 | +5,62 % | Medigene: Zurückziehung - 18.11.2025 | ||
| BIOFRONTERA | 2,670 | +2,69 % | PTA-Adhoc: Biofrontera AG: Finanzprognose für das Geschäftsjahr 2026 | DJ PTA-Adhoc: Biofrontera AG: Finanzprognose für das Geschäftsjahr 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Prognose / Gesamtjahr
Biofrontera AG:... ► Artikel lesen | |
| CLINUVEL | 6,195 | +0,32 % | Clinuvel Pharmaceuticals Limited: CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies | EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery... ► Artikel lesen | |
| EDITAS MEDICINE | 2,204 | +0,09 % | Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates | Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company's first-in-human clinical... ► Artikel lesen | |
| ASEP MEDICAL | 0,163 | +0,62 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,250 | +13,04 % | Should you sell your Cellectar Biosciences stock? | ||
| CARDIFF ONCOLOGY | 1,656 | -0,96 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update | Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of... ► Artikel lesen | |
| CLEAN HARBORS | 246,70 | -1,87 % | Depot Connect International Streamlines Portfolio with Sale of Industrial and Rail Services to Clean Harbors | TAMPA, Fla., Feb. 19, 2026 /PRNewswire/ -- Depot Connect International (DCI) announced today that it has entered into a definitive agreement to sell its Industrial Services and Rail Services... ► Artikel lesen | |
| MESOBLAST | 1,270 | -0,78 % | Mesoblast mit wachsendem Stammzellgeschäft - folgen Eli Lilly und Novartis? | ||
| LIR LIFE SCIENCES | 0,562 | +2,55 % | EQS-Media: First-Mover mit erheblichem Skalierungspotenzial: LIR Life Sciences setzt Innovations-Roadmap fort | EQS-Media / 06.02.2026 / 16:20 CET/CEST
LIR Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), LIR oder das Unternehmen, freut sich bekannt zu geben, dass es mit "Neuland Laboratories Limited"... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,240 | +0,90 % | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,770 | -1,91 % | CStone Pharmaceuticals: CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial | CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,520 | +3,28 % | Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) | Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 116,00 | -4,13 % | Palvella Therapeutics stock rating maintained at Buy by Clear Street | ||
| PURPLE BIOTECH | 4,260 | 0,00 % | XFRA 1YI0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPURPLE BIOT.LTD... ► Artikel lesen |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,240 Euro und damit +1,79 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.